A Different Kind of Precision Medicine

We are building a pipeline of targeted cancer therapies by harnessing both our macrocycle platform and our expertise in structure-based design.

Our pipeline consists of innovative investigational therapies designed to address key limitations of existing cancer therapies. We are developing a suite of precision oncology assets, including small molecule, orally available targeted therapies designed to bind to their targets with greater precision and affinity than other kinase inhibitors, and a potentially first-in-class Claudin18.2 antibody-drug conjugate that has the potential to address unmet need in gastrointestinal cancers.

Repotrectinib (ROS1/TRK)1

Early Stage Clinical Development
Late Stage Clinical Development
Regulatory Submission

TRIDENT-1: Advanced NSCLC (ROS1) And Solid Tumors (NTRK)


CARE: Pediatric Advanced Solid Tumors


TRIDENT-2: KRAS-Targeting Combination


Elzovantinib (TPX-0022) (MET)1

SHIELD-1: Advanced Solid Tumors


SHIELD-2: EGFR Combination2


TPX-0046 (RET)3

SWORD-1: Advanced Solid Tumors


TPX-0131 (ALK)3

FORGE-1: Advanced NSCLC



Advanced solid tumors


Discovery Programs3



p21 Activated Kinase


Multiple GTPase Oncology Targets


1Turning Point retains worldwide rights, except in Greater China (partnered with ZaiLab)

2Clinical collaboration with EQRx.

3Turning Point retains worldwide rights.

4Turning Point licensed worldwide rights from LaNova Medicines (excluding Greater China and South Korea).

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb